Sarepta Therapeutics Inc (NASDAQ:SRPT) shares gapped up prior to trading on Wednesday . The stock had previously closed at $100.61, but opened at $99.95. Sarepta Therapeutics shares last traded at $102.12, with a volume of 91,472 shares trading hands.
A number of equities analysts have weighed in on SRPT shares. Guggenheim started coverage on shares of Sarepta Therapeutics in a report on Friday, November 1st. They issued a “buy” rating and a $183.00 price target on the stock. Citigroup decreased their price target on shares of Sarepta Therapeutics from $185.00 to $180.00 and set a “buy” rating on the stock in a report on Friday, September 27th. William Blair reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, August 9th. Oppenheimer reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, October 8th. Finally, Credit Suisse Group decreased their price target on shares of Sarepta Therapeutics from $201.00 to $185.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $187.78.
The stock’s 50 day moving average price is $86.25 and its 200 day moving average price is $112.71. The company has a current ratio of 6.31, a quick ratio of 7.84 and a debt-to-equity ratio of 0.49. The firm has a market cap of $7.45 billion, a PE ratio of -17.85 and a beta of 2.19.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.35). Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 55.44%. The business had revenue of $99.04 million during the quarter, compared to analysts’ expectations of $98.49 million. During the same period in the prior year, the business posted ($1.15) EPS. The business’s revenue was up 26.2% on a year-over-year basis. Analysts forecast that Sarepta Therapeutics Inc will post -5.9 earnings per share for the current year.
In other Sarepta Therapeutics news, Director Richard Barry bought 5,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were acquired at an average price of $87.49 per share, with a total value of $437,450.00. Following the purchase, the director now owns 3,183,756 shares in the company, valued at approximately $278,546,812.44. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael W. Bonney bought 2,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $86.74 per share, for a total transaction of $173,480.00. Following the purchase, the director now owns 7,051 shares in the company, valued at approximately $611,603.74. The disclosure for this purchase can be found here. In the last three months, insiders bought 14,500 shares of company stock worth $1,327,480. Insiders own 6.60% of the company’s stock.
Several hedge funds have recently modified their holdings of SRPT. Evolution Wealth Advisors LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $25,000. Trust Co. of Vermont increased its stake in Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock worth $27,000 after buying an additional 170 shares during the period. Quad Cities Investment Group LLC increased its stake in Sarepta Therapeutics by 100.0% during the 3rd quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock worth $30,000 after buying an additional 200 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth $32,000. Finally, LS Investment Advisors LLC purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth $36,000. 92.41% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile (NASDAQ:SRPT)
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: What is meant by holder of record?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.